TNOA Journal of Ophthalmic Science and Research

: 2022  |  Volume : 60  |  Issue : 4  |  Page : 330-

Chlorpromazine-Induced cataract and corneal pigmentation

Sarvesswaran Prakash 
 Department of General Ophthalmology, Aravind Eye Hospital and Post Graduate Institute of Ophthalmology, Tirunelveli, Tamil Nadu, India

Correspondence Address:
Sarvesswaran Prakash
Aravind Eye Hospital and Post Graduate Institute of Ophthalmology, Tirunelveli, Tamil Nadu

How to cite this article:
Prakash S. Chlorpromazine-Induced cataract and corneal pigmentation.TNOA J Ophthalmic Sci Res 2022;60:330-330

How to cite this URL:
Prakash S. Chlorpromazine-Induced cataract and corneal pigmentation. TNOA J Ophthalmic Sci Res [serial online] 2022 [cited 2023 Mar 24 ];60:330-330
Available from:

Full Text

Chlorpromazine is used in treating schizophrenia but on long-term usage can cause irreversible ocular toxicity affecting the cornea, conjunctiva, and lens.[1] It is hypothesised that phenothiazines denature proteins when exposed to light; the proteins then become opacified and are deposited in ocular tissues.[2],[3],[4],[5] Herewith, we report a 54-year-old chronic schizophrenia patient who was treated with chlorpromazine hydrochloride 300 mg/d for the past 15 years. On examination, the visual acuity was 6/9 in both eyes. On slit lamp examination, both eyes revealed discrete yellow refractile deposits on the corneal stroma and characteristic bilateral stellate-shaped anterior sub-capsular cataract [Figure 1]. Fundus examination was normal in both eyes.{Figure 1}

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consents forms. In the form patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.


1Greiner AC, Berry K. Skin pigmentation and corneal and lens opacitieswith prolonged chlorpromazine therapy. Can Med Assoc J 1964;90:663-5.
2Howard RO, McDonald CJ, Dunn B, Creasey WA. Experimental chlorpromazine cataracts. Invest Ophthalmol 1969;8:413-21.
3Deluise VP, Flynn JT. Asymmetric anterior segment changes induced by chlorpromazine. Ann Ophthalmol 1981;13:953-5.
4Siddall JR. The ocular toxic findings with prolonged and high dosage chlorpromazine intake. Arch Ophthalmol 1965;74:460-4.
5Webber SK, Domniz Y, Sutton GL, Rogers CM, Lawless MA. Corneal deposition after high-dose chlorpromazine hydrochloride therapy. Cornea 2001;20:217-9.